CADTH is undertaking a project to assess the clinical and cost-effectiveness of new drugs for the treatment of patients with type 2 diabetes. These new drugs are in three classes: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogues, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. As part of this project, recommendations from the CADTH Canadian Drug Expert Committee (CDEC) will be developed.
This project is an update to two large projects on pharmacotherapy for type 2 diabetes completed by CADTH in the past: an evaluation of second- and third-line therapies for type 2 diabetes originally published in 2010 and an update to this evaluation in 2013.
The following components have been completed:
- a science report (clinical and economic evaluations)
- a recommendations report on second-line therapies.
Reports related to third-line therapies are in development.